Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 241600
Ivosidenib is an investigational first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein and is a highly targeted investigational medicine for the treatment of patients with cancers that harbor an IDH1 mutation. IDH1 is a metabolic enzyme that is mutated in a wide range of cancers, including acute myeloid leukemia, cholangiocarcinoma and glioma. Ivosidenib is currently under U.S. FDA priority review for IDH1m R/R AML patients with a PDUFA action date of August 21, 2018.
IPSCIO Record ID: 328906
At the Closing, Seller shall sell, assign, transfer and convey all of Sellerâ€™s and the other Seller Entitiesâ€™ right, title and interest as of the Closing in and to the Purchased Assets, which include any and all Intellectual Property primarily used, or held primarily for use, in the operation of the Business or set forth in the Business Intellectual Property.
Effective as of the Closing, Seller grants to Purchaser a worldwide, non-exclusive, perpetual, irrevocable, with Sellerâ€™s prior written consent, sub-licensable license to all Intellectual Property that is
(a) owned by Seller and its Subsidiaries as of the Closing Date,
(b) required for the research, development, manufacturing, use or commercialization of the Products, and
(c) not included in the Business Intellectual Property solely for the purpose of Exploiting the Products in the Business Field.
Seller hereby grants to Purchaser and its Affiliates a limited, worldwide, non-exclusive, non-transferable, sublicensable, royalty-free right to continue to use the Sellers Name and Marks on packaging, labeling, and educational, payer and marketing materials, including online materials, associated with TIBSOVOÂ® until the later of (i) the date that is eighteen (18) month anniversary of Closing and (ii) the date that is twelve (12) months after Purchaserâ€™s receipt of all necessary approvals from the FDA for replacement packaging associated with TIBSOVOÂ®, and, as permitted by the Transition Services Agreement for the term of the applicable service. Purchaser and its Affiliates shall have the right to grant sublicenses solely (A) with the prior written consent of Seller (such consent not to be unreasonably withheld, conditioned or delayed) or (B) consistent with licenses or sublicenses granted prior to Closing under the Specified Business Contracts.
From the Closing Date until the Loss of Exclusivity with respect to each Earn-Out Product, Purchaser and its Affiliates may not, directly or indirectly, by a sale or swap of assets, merger, reorganization, joint venture, lease, license or any other similar transaction or arrangement, sell, transfer, convey or otherwise dispose of their respective rights in and to such Earn-Out Product to a third party.
TIBSOVO means any product containing or comprising ivosidenib, NDC 71334-100.
Vorasidenib means an isocitrate dehydrogenase-1 & 2 (IDH1 & 2) inhibitor that has the compound AG-881 as its active ingredient.
Vorasidenib Companion Diagnostic Test means the companion diagnostic test used in connection with Vorasidenib that identifies IDH1 and IDH2 mutations in glioma patient samples.
Combination Product means an Earn-Out Product that is comprised of or contains TIBSOVO or Vorasidenib together with one or more other active ingredients (other than TIBSOVO or Vorasidenib), whether in the same or different formulations, and is sold either as a fixed dose or as separate doses as one product.
Business means the worldwide oncology business, operations, activities and programs of Seller and its Subsidiaries as of immediately prior to the Closing with respect to the discovery, research, development, manufacture, registration, commercialization, importation, distribution, sale and marketing of chemical or biological entities, pharmaceutical products, medicines, therapies, compounds, programs, or in vitro diagnostic or other devices, in each case, for patients in the areas of hematologic malignancies, solid tumors and other malignant diseases (collectively, the Business Field), including (a) all activities of Seller and its Subsidiaries as of immediately prior to the Closing related to ivosidenib (TIBSOVOÂ®), enasidenib (IDHIFAÂ®), vorasidenib, AG-270 and AG-636 and the products listed the Seller Disclosure Schedules (including as conducted through joint ventures, collaborations or similar arrangements) as of immediately prior to the Closing, and (b) any and all applications of such chemical or biological entities, pharmaceutical products, medicines, therapies, compounds, programs or in vitro diagnostic or other devices in any field, including any Retained Businesses Field.
The vorasidenib field of use is as an investigational, brain-penetrant, dual inhibitor of mutant IDH1 and IDH2 which is currently being studied in the registration-enabling Phase 3 INDIGO study in patients with IDH-mutant low-grade glioma; AG-270, an investigational first-in-class methionine adenosyltransferase 2a (MAT2A) inhibitor being evaluated in combination with taxanes in patients with methylthioadenosine phosphorylase (MTAP)-deleted non-small cell lung cancer and pancreatic cancer; AG-636, a novel inhibitor of dihydroorotate dehydrogenase (DHODH); and Sellerâ€™s oncology research programs.
Collectively, the Business Field is chemical or biological entities, pharmaceutical products, medicines, therapies, compounds, programs, or in vitro diagnostic or other devices, in each case, for patients in the areas of hematologic malignancies, solid tumors and other malignant diseases.
IPSCIO Record ID: 239202
Pursuant to the License Agreement, Licensee will initially be responsible for the development and commercialization of Licensed Products in acute myeloid leukemia (AML) and cholangiocarcinoma in the Territory, as well as other indications that the parties mutually agree to in the future. Licensee will also be responsible, at the Companyâ€™s discretion, for the development and commercialization of Licensed Products in brain cancer indications in the Territory. The Company has granted Licensee specified intellectual property licenses to enable Licensee to perform its obligations and exercise its rights under the License Agreement, including license grants to enable Licensee to conduct development and commercialization activities pursuant to the terms of the License Agreement.
Ivosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer.